Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Methane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 4/20 | 0.39 |
| ▸ | MMP9 | P14780 | 4/20 | 0.39 |
| ▸ | MMP8 | P22894 | 4/20 | 0.39 |
| ▸ | MMP13 | P45452 | 4/20 | 0.39 |
| ▸ | MMP12 | P39900 | 3/20 | 0.39 |
| ▸ | MMP14 | P50281 | 3/20 | 0.39 |
| ▸ | MMP16 | P51512 | 3/20 | 0.39 |
| ▸ | MMP1 | P03956 | 2/20 | 0.39 |
| ▸ | MMP3 | P08254 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | MYC | P01106 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | DDX3X | O00571 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL8444351 | 0.98 | ALDH1A1 (0.47) | ALDH1A1KDM4EHPGDMMP2MMP9 | |
| Methane SCHEMBL1304330 | 0.96 | ALDH1A1 (0.50) | ALDH1A1KDM4EHPGDMMP2MMP9 | |
| SCHEMBL5016601 | 0.94 | ALDH1A1 (0.52) | ALDH1A1KDM4EHPGDMMP2MMP9 | |
| SCHEMBL11437015 | 0.94 | ALDH1A1 (0.47) | ALDH1A1KDM4EHPGDMMP2MMP9 | |
| Lithium Ion SCHEMBL814018 | 0.94 | ALDH1A1 (0.47) | ALDH1A1KDM4EHPGDMMP2MMP9 | |
| SCHEMBL10780305 | 0.94 | ALDH1A1 (0.47) | ALDH1A1KDM4EHPGDMMP2MMP9 | |
| SCHEMBL2526741 | 0.94 | ALDH1A1 (0.47) | ALDH1A1KDM4EHPGDMMP2MMP9 | |
| Lithium Ion SCHEMBL2524033 | 0.94 | ALDH1A1 (0.47) | ALDH1A1KDM4EHPGDMMP2MMP9 | |
| SCHEMBL2522970 | 0.94 | ALDH1A1 (0.47) | ALDH1A1KDM4EHPGDMMP2MMP9 | |
| SCHEMBL987616 | 0.94 | ALDH1A1 (0.52) | ALDH1A1KDM4EHPGDMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1669065-B1 | DRUG CONTAINING (2R)-2-PROPYLOCTANOIC ACID AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2012-07-18 | — | — | EP | disclosed |
| US-8053599-B2 | Drug containing (2R)-2-propyloctanoic acid as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-11-08 | — | — | US | disclosed |
| US-20070105956-A1 | Drug containing (2r)-2-propyloctanoic acid as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070066686-A1 | Infusion preparation containing (2r)-2-propyloctanoic acid as at the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-22 | — | — | US | disclosed |
| EP-1669065-A1 | DRUG CONTAINING (2R)-2-PROPYLOCTANOIC ACID AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-14 | — | — | EP | disclosed |
| EP-1669066-A1 | INFUSION PREPARATION CONTAINING (2R)-2-PROPYLOCTANOIC ACID AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105956-A1 | Drug containing (2r)-2-propyloctanoic acid as the active ingredient | PSEN2, PRNP, GRIK5 | ALDH1A1 1757/4885KDM4E 3300/4885HPGD 375/4885 |
| US-20070066686-A1 | Infusion preparation containing (2r)-2-propyloctanoic acid as at the active ingredient | PARK7, IDE, ATP6V1B2 | ALDH1A1 2117/4885KDM4E 3979/4885HPGD 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.